Publication:
18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?

dc.contributor.authorGeorgi, Thomas W
dc.contributor.authorKluge, Regine
dc.contributor.authorKurch, Lars
dc.contributor.authorChavdarova, Lidia
dc.contributor.authorHasenclever, Dirk
dc.contributor.authorStoevesandt, Dietrich
dc.contributor.authorPelz, Tanja
dc.contributor.authorLandman-Parker, Judith
dc.contributor.authorWallace, W Hamish
dc.contributor.authorKarlen, Jonas
dc.contributor.authorFernández-Teijeiro, Ana
dc.contributor.authorCepelova, Michaela
dc.contributor.authorFosså, Alexander
dc.contributor.authorBalwierz, Walentyna
dc.contributor.authorAttarbaschi, Andishe
dc.contributor.authorAmmann, Roland A
dc.contributor.authorPears, Jane
dc.contributor.authorHraskova, Andrea
dc.contributor.authorUyttebroeck, Anne
dc.contributor.authorBeishuizen, Auke
dc.contributor.authorDieckmann, Karin
dc.contributor.authorLeblanc, Thierry
dc.contributor.authorDaw, Stephen
dc.contributor.authorBaumann, Julia
dc.contributor.authorKörholz, Dieter
dc.contributor.authorSabri, Osama
dc.contributor.authorMauz-Körholz, Christine
dc.date.accessioned2023-01-25T10:06:38Z
dc.date.available2023-01-25T10:06:38Z
dc.date.issued2018-04-13
dc.description.abstractTo determine whether the current 18F-FDG PET response criterion for skeletal involvement in Hodgkin lymphoma (HL) is suitable, we performed a systematic evaluation of the different types of skeletal involvement and their response on PET after 2 cycles of chemotherapy (PET-2). A secondary objective was to observe the influence of the initial uptake intensity (measured as qPET) and initial metabolic tumor volume (MTV) of skeletal lesions on the PET-2 response. Methods: The initial PET scans of 1,068 pediatric HL patients from the EuroNet-PHL-C1 trial were evaluated for skeletal involvement by central review. Three types of skeletal lesions were distinguished: PET-only lesions (those detected on PET only), bone marrow (BM) lesions (as confirmed by MRI or BM biopsy), and bone lesions. qPET and MTV were calculated for each skeletal lesion. All PET-2 scans were assessed for residual tumor activity. The rates of complete metabolic response for skeletal and nodal involvement on PET-2 were compared. Results: Of the 1,068 patients, 139 (13%) showed skeletal involvement (44 PET-only, 32 BM, and 63 bone). Of the 139 patients with skeletal involvement, 101 (73%) became PET-2-negative in the skeleton and 94 (68%) became PET-2-negative in the lymph nodes. The highest number of PET-2-negative scans in the skeleton was 42 (95%) in the 44 PET-only patients, followed by 22 skeletal lesions (69%) in the 32 BM patients and 37 (59%) in the 63 bone patients. Lesions that became PET-2-negative showed a lower initial median qPET (2.74) and MTV (2 cm3) than lesions that remained PET-2-positive (3.84 and 7 cm3, respectively). Conclusion: In this study with pediatric HL patients, the complete response rate for skeletal involvement on PET-2 was similar to that for nodal involvement. Bone flare seemed to be irrelevant. Overall, the current skeletal PET response criterion-comparison with the local skeletal background-is well suited. The initial qPET and MTV of skeletal lesions were predictive of the PET-2 result. Higher values for both parameters were associated with a worse PET-2 response.
dc.identifier.doi10.2967/jnumed.117.205633
dc.identifier.essn1535-5667
dc.identifier.pmid29653979
dc.identifier.unpaywallURLhttp://jnm.snmjournals.org/content/59/10/1524.full.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12345
dc.issue.number10
dc.journal.titleJournal of nuclear medicine : official publication, Society of Nuclear Medicine
dc.journal.titleabbreviationJ Nucl Med
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.organizationHospital Universitario Virgen Macarena
dc.organizationHospital Universitario Virgen Macarena
dc.page.number1524-1530
dc.pubmedtypeJournal Article
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectHodgkin lymphoma
dc.subjectbone involvement
dc.subjectbone marrow involvement
dc.subjectinterim PET
dc.subjectresponse adapted treatment
dc.subject.meshAdolescent
dc.subject.meshBone Marrow Neoplasms
dc.subject.meshBone Neoplasms
dc.subject.meshChild
dc.subject.meshFemale
dc.subject.meshFluorodeoxyglucose F18
dc.subject.meshHodgkin Disease
dc.subject.meshHumans
dc.subject.meshInduction Chemotherapy
dc.subject.meshMale
dc.subject.meshPositron-Emission Tomography
dc.subject.meshRetrospective Studies
dc.subject.meshTreatment Outcome
dc.title18F-FDG PET Response of Skeletal (Bone Marrow and Bone) Involvement After Induction Chemotherapy in Pediatric Hodgkin Lymphoma: Are Specific Response Criteria Required?
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number59
dspace.entity.typePublication

Files